FDA OTC labeling "statement of identity" survey to involve 216 participants.
This article was originally published in The Tan Sheet
Executive Summary
OTC COMBO ACTIVE INGREDIENTS LISTING ON PRINCIPAL DISPLAY PANEL TO BE EVALUATED in a consumer comprehension labeling study planned by FDA. The purpose of the study, which addresses the "statement of identity" on OTC drug product labels, "is to investigate consumers' perceptions, processing and evaluation of the placement of active ingredient information on the front and/or back portion of the product package," FDA says in an Aug. 6 "supporting statement" on the proposed research.